CHAPEL HILL, N.C.--(BUSINESS WIRE)--Jan. 24, 2003--POZEN Inc.
(NASDAQ:POZN), a pharmaceutical development company with a portfolio
of product candidates for the treatment of migraine, today announced
it will release fourth quarter and full-year 2002 financial results on
Thursday, January 30, 2003, before the financial markets open. The
release will be followed by a conference call at 11:00 a.m. Eastern
time, hosted by John R. Plachetka, chairman, president, and chief
executive officer, and Matthew E. Czajkowski, chief financial officer.
The conference call will be simulcast live on the Internet, and
can be accessed by logging on to www.pozen.com. A replay will be
available for seven days and can be accessed by going to POZEN's
website and clicking on Investor Overview.
POZEN is a pharmaceutical development company committed to
building a portfolio of products with significant commercial potential
in select therapeutic areas. POZEN's initial focus is on developing
products for migraine therapy, a global market expected to exceed $3
billion this year. The company's common stock is traded on The Nasdaq
Stock Market under the symbol "POZN."
Chief Financial Officer
Director, Investor Relations